

Supplementary Materials

for

Loss of recognition of SARS-CoV-2 B.1.351 variant spike epitopes but overall preservation of T cell immunity

Catherine Riou, Roanne Keeton, Thandeka Moyo-Gwete, Tandile Hermanus, Prudence Kgagudi, Richard Baguma, Houriiyah Tegally, Deelan Doolabh, Arash Iranzadeh, Lynn Tyers, Hygon Mutavhatsindi, Marius B. Tincho, Ntombi Benede, Gert Marais, Lionel R. Chinhoyi, Mathilda Mennen, Sango Skelem, Elsa du Bruyn, Cari Stek, SA-CIN[†], Tulio de Oliveira, Carolyn Williamson, Penny L. Moore, Robert J. Wilkinson, Ntobeko A. B. Ntusi, Wendy A. Burgers

[†]South African Cellular Immunology Network (SA-CIN) collaborators listed at the end of this document

This PDF file contains:

Fig. S1
Fig. S2
Table S1
SA-CIN (South African Cellular Immunology Network) collaborator list




Fig. S1. Genomic sequencing confirmation of SARS-CoV-2 B.1.351 infection of COVID-19 second wave patients. (A) A time-resolved maximum clade credibility phylogeny of 2621 global SARS-CoV-2 sequences. Sequences from South Africa (n=209) are denoted with tip points. The B.1.351 (501Y.V2) cluster is highlighted in red, and the genomes from this study (n=19) are shown in yellow, all falling in that cluster. (B) Spike sequence in patients recruited during the second wave, indicating amino acid changes. Blue shading corresponds to the ancestral strain (i.e. wild type, WT) amino acids and red shading to B.1.351 strain amino acids. (-) corresponds to amino acid deletions. **: Patients exhibiting a detectable CD4 T cell response to the WT and B.1.351 peptide pools, *: Patient exhibiting a detectable CD4 T cell response to the WT peptide pool.




Fig. S2. Graphical representation of study approach. (A) SARS-CoV-2 spike protein is depicted, demonstrating the design of ancestral and B.1.351 variant peptides used in the immunological assays. (B) PBMC from patients recruited during the first or second wave of the pandemic in South Africa were stimulated with pools of peptides covering full spike, or smaller pools spanning only the regions mutated in B.1.351, with wild type (WT) and corresponding mutated versions.

Table S1. Peptides included in the ancestral and B.1.351 peptide pools.

Mutations of interest	Strain	Position aa (start)	Position aa (stop)	Sequence	Previously described
L18F	ancestral	6	20	VLLPLVSSQCVNL <u>T</u> TT	Mateus et al.
L18F	ancestral	11	25	VSSQCVN <u>L</u> TTT <u>R</u> QLP	Tarke et al.
D80A	ancestral	73	87	TNGTKRF <u>D</u> NPVLPFN	
D80A	ancestral	78	92	RF <u>D</u> NPVLPFNDGVYF	Tarke et al.
D215G	ancestral	206	220	KHTPINLVR <u>D</u> LPQGF	Tarke et al.
D215G	ancestral	208	222	TPINLVR <u>D</u> LPQGFSA	Peng et al.
D215G	ancestral	211	225	NLVR <u>D</u> LPQGFSALEP	Peng et al.
242-244del/R246I	ancestral	236	250	TRFQT <u>L</u> AL <u>H</u> RSYLT	Mateus et al.
242-244del/R246I	ancestral	241	255	LLAL <u>H</u> RSYLT <u>P</u> GDSS	Mateus et al.
K417N	ancestral	411	425	APGQT <u>G</u> KIADNYKL	
K417N	ancestral	416	430	<u>G</u> KIADNYKLPDDFT	Mateus et al.
E484K	ancestral	476	490	GSTPCNG <u>V</u> EGFNCYF	
E484K	ancestral	481	495	NG <u>V</u> EGFNCYFPLQSY	
N501Y	ancestral	492	506	LQS <u>Y</u> GFQPT <u>N</u> GYQ	
N501Y	ancestral	496	510	GFQPT <u>N</u> GYQPYRV	
A701V	ancestral	701	715	<u>A</u> ENSVAYSNNNSIAIP	Mateus et al.
L18F	B1.351	6	20	VLLPLVSSQCVN <u>F</u> TT	
L18F	B1.351	11	25	VSSQCVN <u>F</u> TT <u>R</u> QLP	
D80A	B1.351	73	87	TNGTKRF <u>A</u> NPVLPFN	
D80A	B1.351	78	92	RF <u>A</u> NPVLPFNDGVYF	
D215G	B1.351	206	220	KHTPINLVR <u>G</u> LPQGF	
D215G	B1.351	208	222	TPINLVR <u>G</u> LPQGFSA	
D215G	B1.351	211	225	NLVR <u>G</u> LPQGFSALEP	
242-244del/R246I	B1.351	236	250	TRFQT <u>L</u> H <u>I</u> SYLT <u>P</u> GD	
242-244del/R246I	B1.351	241	255	L <u>H</u> ISYLT <u>P</u> GD <u>S</u> SGW	
K417N	B1.351	411	425	APGQT <u>G</u> N <u>I</u> ADNYKL	
K417N	B1.351	416	430	<u>G</u> NIADNYKLPDDFT	
E484K	B1.351	476	490	GSTPCNG <u>V</u> K <u>G</u> FNCYF	
E484K	B1.351	481	495	NG <u>V</u> KGFNCYFPLQSY	
N501Y	B1.351	492	506	LQS <u>Y</u> GFQPT <u>Y</u> GYQ	
N501Y	B1.351	496	510	GFQPT <u>Y</u> GYQPYRV	
A701V	B1.351	701	715	<u>V</u> ENSVAYSNNNSIAIP	

List and sequence of 15-mer peptides contained in the ancestral (WT) and B.1.351 peptide pools. References of previously described reactive peptides are provided in the last column. aa: amino acid. The site of mutation in B.1.351 is underlined in the peptide sequence.

South African Cellular Immunology Network (SA-CIN) collaborators

Fatima Abrahams¹, Frances Ayres², Elloise du Toit³, Rene T. Goliath¹, Willem Hanekom⁴, Diana Hardie³, Nei-Yuan Hsiao³, Henrik Kloverpris⁴, Stephen Korsman³, Francisco Lakay¹, Bronwen Lambson², Alasdair Leslie⁴, Zanele Makhado², Moepeng Maseko³, Donald Mhlanga², Michelle Naidoo³, Zaza Ndhlovu⁴, Amkele Ngomti³, Brent Oosthuysen², Sheena Ruzive¹, Alex Sigal⁴, Tamryn Smith³, Ziyaad Valley-Omar³, Dieter van der Westhuizen⁵, Kennedy Zvinairo¹

¹Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town; Observatory 7925, South Africa

²National Institute for Communicable Diseases of the National Health Laboratory Services; Johannesburg, South Africa

³Division of Medical Virology, Department of Pathology, University of Cape Town; Observatory 7925, South Africa

⁴Africa Health Research Institute; Durban, South Africa

⁵Division of Chemical Pathology, Department of Pathology, University of Cape Town; Observatory 7925, South Africa